Why the Clinuvel (ASX:CUV) share price is climbing higher today

The Clinuvel Pharmaceuticals Limited (ASX: CUV) share price

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Clinuvel Pharmaceuticals Limited (ASX: CUV) share price has returned from its trading halt and is pushing higher on Tuesday afternoon.

At the time of writing, the biopharmaceutical company's shares are up almost 1% to $22.11.

Why is the Clinuvel share price pushing higher?

Investors have been buying the company's shares today following the release of an update on its Scenesse product.

Scenesse is the first treatment to provide erythropoietic protoporphyria patients (EPP) with protection from the wavelengths of light that cause phototoxicity. It reduces the number and severity of reactions and increases the amount of time that sufferers can be exposed to light.

Management notes that since the drug has been made available in Europe in 2016 and the United States in 2020, patients report that they have been given a freedom they never had imagined.

The good news for Australians with EPP, is that Clinuvel has just received approval for Scenesse to be prescribed in Australia. It will soon be listed on the Australian Therapeutic Goods Register following approval from the Therapeutic Goods Administration (TGA).

The release explains that Scenesse will be registered for the indication prevention of phototoxicity in adult patients with EPP. It will be available as a prescription medication, to be administered by trained and accredited healthcare professionals.

In light of the latter, the company will implement a comprehensive training and accreditation program and ensure that healthcare professionals are provided with information in line with the Australian approval.

Clinuvel's Chief Scientific Officer, Dr Dennis Wright, commented: "Our team is delighted that an Australian innovation is returning home as an approved drug and will be made available for Australian EPP patients."

"I recognise the work of patients, physicians, TGA staff and our team to facilitate today's outcome, which is the result of many years of engagement and dialogue. Our objective has been clear: to find ways to enable all EPP patients worldwide to access the first ever treatment for this disorder which is largely misunderstood but which causes patients a lifelong imprisonment, away from a normal outdoor life," he concluded.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Share Gainers

3 ASX All Ords shares up 50%+ in March

These ASX shares have been on fire this month. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Share Gainers

Why Mesoblast, Patriot Battery Metals, Sigma, and Zip shares are pushing higher

These shares are having a good session on hump day. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Consumer Staples & Discretionary Shares

If you'd put $20,000 in this ASX retail stock at the start of 2023, you'd have $134,000 now

This online retailer has executed a remarkable turnaround for its investors.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was back to earth for ASX shares this Tuesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »